Experience with the once-yearly histrelin (GnRHa) subcutaneous implant in the treatment of central precocious puberty

Katherine A. Lewis, Erica Eugster

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

In 2007, a hydrogel histrelin implant was approved for the treatment of children with central precocious puberty (CPP). Children with CPP commonly have reduced height potential due to premature closure of the epiphyseal growth plates from exposure to sex steroids. Gonadotropin-releasing hormone analog (GnRHa) treatment halts puberty and allows for improvement of adult height. A hydrogel implant delivery system utilizing the potent GnRHa, histrelin, was first developed for use in men with prostate cancer. A once yearly histrelin subcutaneous implant was subsequently developed for the treatment of children with CPP. Studies to date have demonstrated safety, tolerability, and effectiveness of this treatment option in patients treated up to 2 years. The most common adverse effects of the implant relate to implant site pain or bruising. Cost of this treatment seems comparable to somewhat higher than the commonly used GnRHa treatment option, depot leuprolide. While long term studies are needed to establish continued efficacy and safety beyond 2 years of treatment, the histrelin implant appears to be an attractive option for GnRHa treatment in patients with CPP.

Original languageEnglish
Pages (from-to)1-5
Number of pages5
JournalDrug Design, Development and Therapy
Issue number3
StatePublished - 2009

Fingerprint

Gonadotropin-Releasing Hormone
Growth Plate
Hydrogel
Therapeutics
Leuprolide
Safety
Puberty
Health Care Costs
Central Precocious Puberty
histrelin
Prostatic Neoplasms
Steroids
Pain

Keywords

  • Central precocious puberty
  • Gonadotropin-releasing-hormone analogs
  • Histrelin
  • Implant

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Pharmacology
  • Drug Discovery

Cite this

@article{8a8ec39d95ea4128a17a0f8a0ba5a8be,
title = "Experience with the once-yearly histrelin (GnRHa) subcutaneous implant in the treatment of central precocious puberty",
abstract = "In 2007, a hydrogel histrelin implant was approved for the treatment of children with central precocious puberty (CPP). Children with CPP commonly have reduced height potential due to premature closure of the epiphyseal growth plates from exposure to sex steroids. Gonadotropin-releasing hormone analog (GnRHa) treatment halts puberty and allows for improvement of adult height. A hydrogel implant delivery system utilizing the potent GnRHa, histrelin, was first developed for use in men with prostate cancer. A once yearly histrelin subcutaneous implant was subsequently developed for the treatment of children with CPP. Studies to date have demonstrated safety, tolerability, and effectiveness of this treatment option in patients treated up to 2 years. The most common adverse effects of the implant relate to implant site pain or bruising. Cost of this treatment seems comparable to somewhat higher than the commonly used GnRHa treatment option, depot leuprolide. While long term studies are needed to establish continued efficacy and safety beyond 2 years of treatment, the histrelin implant appears to be an attractive option for GnRHa treatment in patients with CPP.",
keywords = "Central precocious puberty, Gonadotropin-releasing-hormone analogs, Histrelin, Implant",
author = "Lewis, {Katherine A.} and Erica Eugster",
year = "2009",
language = "English",
pages = "1--5",
journal = "Drug Design, Development and Therapy",
issn = "1177-8881",
publisher = "Dove Medical Press Ltd.",
number = "3",

}

TY - JOUR

T1 - Experience with the once-yearly histrelin (GnRHa) subcutaneous implant in the treatment of central precocious puberty

AU - Lewis, Katherine A.

AU - Eugster, Erica

PY - 2009

Y1 - 2009

N2 - In 2007, a hydrogel histrelin implant was approved for the treatment of children with central precocious puberty (CPP). Children with CPP commonly have reduced height potential due to premature closure of the epiphyseal growth plates from exposure to sex steroids. Gonadotropin-releasing hormone analog (GnRHa) treatment halts puberty and allows for improvement of adult height. A hydrogel implant delivery system utilizing the potent GnRHa, histrelin, was first developed for use in men with prostate cancer. A once yearly histrelin subcutaneous implant was subsequently developed for the treatment of children with CPP. Studies to date have demonstrated safety, tolerability, and effectiveness of this treatment option in patients treated up to 2 years. The most common adverse effects of the implant relate to implant site pain or bruising. Cost of this treatment seems comparable to somewhat higher than the commonly used GnRHa treatment option, depot leuprolide. While long term studies are needed to establish continued efficacy and safety beyond 2 years of treatment, the histrelin implant appears to be an attractive option for GnRHa treatment in patients with CPP.

AB - In 2007, a hydrogel histrelin implant was approved for the treatment of children with central precocious puberty (CPP). Children with CPP commonly have reduced height potential due to premature closure of the epiphyseal growth plates from exposure to sex steroids. Gonadotropin-releasing hormone analog (GnRHa) treatment halts puberty and allows for improvement of adult height. A hydrogel implant delivery system utilizing the potent GnRHa, histrelin, was first developed for use in men with prostate cancer. A once yearly histrelin subcutaneous implant was subsequently developed for the treatment of children with CPP. Studies to date have demonstrated safety, tolerability, and effectiveness of this treatment option in patients treated up to 2 years. The most common adverse effects of the implant relate to implant site pain or bruising. Cost of this treatment seems comparable to somewhat higher than the commonly used GnRHa treatment option, depot leuprolide. While long term studies are needed to establish continued efficacy and safety beyond 2 years of treatment, the histrelin implant appears to be an attractive option for GnRHa treatment in patients with CPP.

KW - Central precocious puberty

KW - Gonadotropin-releasing-hormone analogs

KW - Histrelin

KW - Implant

UR - http://www.scopus.com/inward/record.url?scp=77953660478&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953660478&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:77953660478

SP - 1

EP - 5

JO - Drug Design, Development and Therapy

JF - Drug Design, Development and Therapy

SN - 1177-8881

IS - 3

ER -